1 Light RW, Girard WM, Jenkinson SG, Georg RB. Parapneumonic effusions. Am J Med. 1980;69:507.
2 Munkholm M, Mortensen J. Mucociliary clearence: pathophysiological aspects. Clin Physiol Funct Imaging. 2014;34(3):171–7.
3 Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am. 2004;18:743.
4 Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Critical Care Med. 2006;174:817–23.
5 Forster S, Maskell N. Bacteriology of complicated parapneumonic effusions. Curr Opin Pulm Med. 2007;13:319–23.
6 Hecker E, Hecker HC, Hecker KA. Pleuraempyem- Behandlungsstrategien unter Berücksichtigung der Ätiologie. Zentralbl Chir. 2013;138:353–79.
7 Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008;16:CD002 312.
8 Schneiter D. Accelerated treatment of postpneumonectomy empyema: a binational long-term study. J Thorac Cardiovasc Surg. 2008;136:179–85.